The relationship between DLQI and DLQI-R scores and disease severity in patients with active psoriasis and chronic urticaria: a cross-sectional observational study


Tabak G. H., DEMİREL ÖĞÜT N.

Archives of Dermatological Research, vol.318, no.1, 2026 (SCI-Expanded, Scopus)

  • Publication Type: Article / Article
  • Volume: 318 Issue: 1
  • Publication Date: 2026
  • Doi Number: 10.1007/s00403-026-04897-w
  • Journal Name: Archives of Dermatological Research
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest), Pharma Collection (ProQuest)
  • Keywords: Health-related quality of life, Psoriasis severity, QoL, Urticaria severity
  • Usak University Affiliated: Yes

Abstract

Psoriasis and chronic urticaria are chronic dermatological diseases that negatively affect quality of life. The Dermatology Life Quality Index (DLQI) is the most commonly used scale in dermatology practice; however, scoring “not relevant” responses (NRR) as zero may underestimate disease burden. We performed this study to compare the correlations of DLQI and DLQI-Relevant (DLQI-R) scores with disease severity in psoriasis and urticaria. A total of 150 adult patients with psoriasis and 150 patients with chronic urticaria diagnosed by a dermatologist were screened for this study. Demographic data, Psoriasis Area Severity Index (PASI) for psoriasis, and Urticaria Activity Score for last 7 days (UAS7) for urticaria were recorded. Patients whose psoriasis and urticaria activity scores were ‘0’ were excluded from the study. All patients completed the DLQI questionnaire. The DLQI-R score was calculated as formulation of DLQI × 10/(10 – NRR count). Spearman correlation analyses were performed. Seventy-two female (64%) and 39 male (36%) psoriasis, and 65 female (73%) and 24 male (27%) patients with chronic urticaria were included. In both groups, there was a strong positive correlation between DLQI and DLQI-R (r = 0.981; p < 0.001 and r = 0.989; p < 0.001). In the psoriasis group, the correlations of DLQI and DLQI-R with PASI were very similar (r = 0.423, r = 0.416). Likewise, in the chronic urticaria group, the correlations of DLQI and DLQI-R with UAS7 were similar. (r = 0.623, r = 0.608). Contrary to expectations, the DLQI-R was not found to be superior to the DLQI in assessing disease-related quality of life. Given the high proportion of patients who provided at least one NRR response, disease-specific health-related quality of life (HRQoL) instruments may complement the DLQI by capturing aspects of quality of life that the generic DLQI items may not adequately address. Therefore, the adoption of disease specific quality of life scales in routine clinical practice would be advantageous.